Search research articles
Contact Us
Filters
Showing results (1-10 of 145) with videos related to
Page
of 15
Sort By:
Expert Opinion on Investigational Drugs
|
July 29, 2003
AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma
Ronald M Bukowski
Oncology (Williston Park, N.Y.)
|
June 16, 2006
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community
Ronald M Bukowski
Current Oncology Reports
|
December 6, 2001
Development of novel signal transduction inhibitors; recent phase I trials
Ronald M Bukowski
Current Oncology Reports
|
January 29, 2011
Biomarkers in renal cell carcinoma: what next?
Ronald M Bukowski
Cancer
|
April 30, 2009
Prognostic factors for survival in metastatic renal cell carcinoma: update 2008
Ronald M Bukowski
Clinical Genitourinary Cancer
|
February 14, 2009
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm
Ronald M Bukowski
Current Oncology Reports
|
February 17, 2009
Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer
Ronald M Bukowski
Expert Opinion on Pharmacotherapy
|
July 1, 2010
Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach
Ronald M Bukowski
Current Oncology Reports
|
April 2, 2008
Randomized trial of bevacizumab in advanced renal cell carcinoma
Ronald M Bukowski
Cancer Management and Research
|
September 21, 2011
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
Ronald M Bukowski
Page
of 15
Search research articles
Search
Showing results (1-10 of 145) with videos related to
Sort By:
Page
of 15
Expert Opinion on Investigational Drugs
|
July 29, 2003
AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma
Ronald M Bukowski
Oncology (Williston Park, N.Y.)
|
June 16, 2006
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community
Ronald M Bukowski
Current Oncology Reports
|
December 6, 2001
Development of novel signal transduction inhibitors; recent phase I trials
Ronald M Bukowski
Current Oncology Reports
|
January 29, 2011
Biomarkers in renal cell carcinoma: what next?
Ronald M Bukowski
Cancer
|
April 30, 2009
Prognostic factors for survival in metastatic renal cell carcinoma: update 2008
Ronald M Bukowski
Clinical Genitourinary Cancer
|
February 14, 2009
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm
Ronald M Bukowski
Current Oncology Reports
|
February 17, 2009
Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer
Ronald M Bukowski
Expert Opinion on Pharmacotherapy
|
July 1, 2010
Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach
Ronald M Bukowski
Current Oncology Reports
|
April 2, 2008
Randomized trial of bevacizumab in advanced renal cell carcinoma
Ronald M Bukowski
Cancer Management and Research
|
September 21, 2011
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
Ronald M Bukowski
Page
of 15